These 2 Numbers Show Why Pfizer Will Beat Merck In 2022
Making medicines to prevent and treat coronavirus infection is big business, and where there's money to be made, there are always winners and losers. Over the last year, returns from Pfizer's (NYSE: PFE) stock have smashed Merck's (NYSE: MRK), rising by over 48% against the other pharma's growth of near 7.5%.
There's reason to believe that Pfizer will be the victor once again in 2022. It all boils down to two numbers, both of which pertain to the company's sales of its coronavirus vaccine, Comirnaty, and its antiviral pill for treating COVID-19 infections, Paxlovid.
Image source: Getty Images.
Source Fool.com
